" class="no-js "lang="en-US"> CYTENA - Medtech Alert
Thursday, March 28, 2024
CYTENA | Pharmtech Focus

CYTENA

About CYTENA

CYTENA

We at cytena CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology.

Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other downstream applications.

Most of the top ten largest pharmaceutical companies have successfully integrated cytena instruments into their workflows to quickly produce monoclonal cell lines for antibody development with minimal risk of cross-contamination. cytena instruments are also used for academic research for various topics including cancer, autoimmune disease and genomic research.

Our instruments provide many benefits including:

Assurance of clonality
Every single cell isolated is imaged to provide assurance of clonality. The image sequence is assigned to the well of the deposited cell and stored for documentation.

Viability
Our instruments gentle handling routinely achieves high cell viability without the need for cell labelling.

Purity
A disposable cartridge is the only component in contact with the cells ensuring no cross-contamination between samples and no cleaning routines.

Easy to use and flexible
Our instruments and software are intuitive, user friendly, and can be readily implemented into existing structures and workflows.

Interested in joining our team?
cytena is a young, dynamic and highly motivated team. We are looking for new team members who also have interest in developing new and innovative products. Feel free to contact us if you have any inquiries on current open positions.

Related Story

BICO’s CYTENA Signs USD 10 Million Deal to Distribute Single Cell Isolators in China to Accelerate Development of Next Generation Therapies

December 8 2021

Today CYTENA, a BICO company, announced it has signed a 2-year deal with Applitech Pharmaceutical Equipment Technology to […]

CYTENA Launches C.STATION, a Fully Automated Platform for Stable Cell Line Development to Streamline Production of Antibody and Gene Therapies

October 19 2021

Today CYTENA, a BICO company, launched C.STATION, a new platform for fully automated stable cell line development. The […]